Literature DB >> 6198076

Defects in natural killer cell activity and interferon response in human lung carcinoma and malignant melanoma.

W L Sibbitt, A D Bankhurst, A J Jumonville, J H Saiki, J H Saiers, R C Doberneck.   

Abstract

The natural killer (NK) activity of peripheral blood mononuclear cells from 25 patients with squamous cell carcinoma of the lung, malignant melanoma, or epitheloid cancers of the gastrointestinal tract was measured by the lysis of 51Cr-labeled K562 target cells. NK activities of many patients with lung cancer or malignant melanoma were decreased relative to normal controls. This abnormality was significantly correlated with advancing stage of disease and the percentage of monocytes in the cell suspensions. Addition of indomethacin or removal of monocytes did not restore depressed NK function to normal levels. Abnormalities of NK function did not appear to be secondary to the presence of mononuclear suppressor cells. The response to interferon was also impaired in patients with advanced disease. The number of effector:target conjugates was normal even in patients with depressed NK function; however, the number of active lytic effectors was decreased. These results imply that the cells which bind tumor targets are present in patients with advanced cancers, but these cells are either immature or functionally inactive.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198076

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors:  Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

2.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

3.  Natural killer and antibody-dependent cellular cytotoxicity in cervical carcinoma patients.

Authors:  M N Satam; J N Suraiya; J J Nadkarni
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 4.  Investigation of NK cell function and their modulation in different malignancies.

Authors:  Gordana Konjevic; Vladimir Jurisic; Viktor Jovic; Ana Vuletic; Katarina Mirjacic Martinovic; Sandra Radenkovic; Ivan Spuzic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

5.  Progressive splenomegaly with increasing extramedullary haematopoiesis in subcutaneous 9L-glioma bearing rats.

Authors:  H Imaya; M Kudo; H Matsuura
Journal:  Int J Exp Pathol       Date:  1993-02       Impact factor: 1.925

6.  [Immune status of patients with bronchial cancer].

Authors:  P Aulenbacher; H G Manke; P Drings
Journal:  Klin Wochenschr       Date:  1987-05-15

7.  Defective interferon-augmented natural killer cell activity in patients with metastatic malignant melanoma.

Authors:  C Müller; H Pehamberger; M Binder; C C Zielinski
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

8.  Natural killer activity of peripheral blood lymphocytes and its relation to histopathological factors of lung cancer.

Authors:  A Terazawa; N Tanaka; N Senou; F Inoue; H Matsuura; A Gouchi; S Fuchimoto; H Mimura; K Orita
Journal:  Jpn J Surg       Date:  1987-07

9.  Tumor growth impedes natural-killer-cell maturation in the bone marrow.

Authors:  John O Richards; Xing Chang; Bradley W Blaser; Michael A Caligiuri; Pan Zheng; Yang Liu
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

10.  Evaluation of the Functional Capacity of NK Cells of Melanoma Patients in an In Vitro Model of NK Cell Contact with K562 and FemX Tumor Cell Lines.

Authors:  Gordana Konjevic; Ana Vuletic; Katarina Mirjacic Martinovic; Ana Krivokuca; Radmila Jankovic; Nada Babovic
Journal:  J Membr Biol       Date:  2017-09-08       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.